As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn's disease by binding to membranebound TNF (mTNF), we created a fluorescent antibody for molecular mTNF imaging in this disease. Topical antibody administration in 25 patients with Crohn's disease led to detection of intestinal mTNF + immune cells during confocal laser endomicroscopy. Patients with high numbers of mTNF + cells showed significantly higher short-term response rates (92%) at week 12 upon subsequent anti-TNF therapy as compared to patients with low amounts of mTNF + cells (15%). This clinical response in the former patients was sustained over a follow-up period of 1 year and was associated with mucosal healing observed in follow-up endoscopy. These data indicate that molecular imaging with fluorescent antibodies has the potential to predict therapeutic responses to biological treatment and can be used for personalized medicine in Crohn's disease and autoimmune or inflammatory disorders.
Crohn's disease is characterized by chronic relapsing inflammation of the intestinal mucosa 1,2 . Patients with this incurable disease can suffer from chronic diarrhea, rectal bleeding, abdominal cramping, stenoses and fistula formation, and many patients require surgical intervention over time 3 . It is the general consensus that inappropriate activation of the mucosal immune system leading to augmented cytokine production contributes to disease pathogenesis 4 and that the proinflammatory cytokine TNF-α has a pivotal role in Crohn's disease immunopathogenesis 2 . TNF is synthesized as a transmembrane protein (mTNF) whose soluble form (sTNF) is released by proteolytic cleavage. Whereas sTNF preferentially binds to TNF receptor 1 on target cells, mTNF binds mainly to TNF receptor 2 (ref. 5).
The functional relevance of TNF in Crohn's disease is highlighted by the clinical efficacy of neutralizing antibodies to TNF such as adalimumab, certolizumab pegol and infliximab [6] [7] [8] . Therapy with antibodies to TNF has been approved for treatment of patients with moderate to severe Crohn's disease. In spite of the clinical efficacy of this treatment, however, about 50% of patients do not respond to adalimumab, as determined by a lack of a 100-point reduction of the clinical activity score (Crohn's disease activity index, CDAI) within 4 weeks after initiation of therapy 8 . These patients demonstrate little or no improvement of clinical symptoms upon anti-TNF therapy but are potentially exposed to side effects such as infections, allergic reactions, skin disorders and lupus-like autoimmunity 9 . A key unmet need is therefore to establish predictive biomarkers for therapeutic responders in order to avoid exposure of nonresponders to anti-TNF therapy, thus enhancing safety and cost-effective use of this treatment. Although patients with elevated C-reactive protein (CRP) levels in the blood have demonstrated higher response rates to anti-TNF treatment 10 , there are currently no additional routine biomarkers that allow the prediction of response to anti-TNF therapy. However, pharmacogenomic research identified an association between therapy response and polymorphisms in apoptosis genes and defined an apoptotic index to predict response to the anti-TNF agent infliximab 11 , but these observations must be validated in larger prospective studies. Thus, the prediction of clinical responsiveness to therapy with antibodies to TNF remains a key clinical problem.
In recent years, endoscopy techniques have rapidly evolved for improved detection of inflammatory and neoplastic lesions [12] [13] [14] [15] . In particular, confocal laser endomicroscopy (CLE) has recently been shown to augment detection of local inflammation and neoplasia in the gastrointestinal tract 16 . Endomicroscopy also permitted
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease the identification of neoplastic lesions during colonoscopy in patients through the use of a labeled heptapeptide derived from a phage library 17 . These findings underline the concept that endomicroscopy might be used for in vivo molecular imaging in patients with gastrointestinal disorders. As antibodies to TNF appear to induce immunosuppression in Crohn's disease by binding to mTNF on target cells 18, 19 , we hypothesized that identification of such mTNF-expressing cells in the mucosa may be used to identify patients who will respond to subsequent anti-TNF therapy. As the antibody to TNF adalimumab is a fully human antibody with high affinity to mTNF 8, 19, 20 , we selected it for the detection of mTNF-expressing cells in the human gut. We found that in vivo molecular imaging with fluorescent antibodies to TNF has the potential to serve as a predictive biomarker for the therapeutic response to adalimumab therapy and might open new avenues for individualized therapy.
RESULTS

Ex vivo molecular imaging with fluorescent antibody to TNF
In order to permit visualization of mTNF + cells through CLE, we labeled the adalimumab antibody with FITC (conforming to good manufacturing practice guidelines) for in vivo use (see Online Methods). On average, 1 adalimumab molecule was labeled with 2.1 fluorescein molecules at 25 °C. Subsequently, we analyzed labeled antibodies by gel electrophoresis and Coomassie staining. Detailed analysis demonstrated that there was no free unbound FITC after the labeling procedure (Supplementary Fig. 1) .
To test the specificity of the labeled antibody for mTNF, we shielded mucosal specimens of patients with Crohn's disease from light with aluminum foil and incubated them with fluorescent adalimumab for 10 min at room temperature. Ex vivo confocal imaging revealed a specific fluorescence signal that allowed identification of mTNFexpressing mucosal cells in the inflamed tissue (Fig. 1a) . We obtained similar results by microscopic analysis of sections (Fig. 1b) .
In subsequent experiments, we analyzed mucosal samples from patients with Crohn's disease by CLE upon treatment with fluorescent adalimumab. Quantitative analysis of the mean number of mucosal mTNF-expressing cells per confocal image revealed that one group of patients had high mean numbers of mTNF + mucosal immune cells (>20 cells per confocal image), whereas another group had low mean numbers of mTNF-expressing cells (<20 cells per image) (Fig. 1c) .
In vivo molecular imaging of intestinal mTNF + immune cells As the labeled antibody was able to detect mTNF, we addressed its potential for in vivo molecular imaging of the mucosa in patients with Crohn's disease. We performed endoscopic examination with the fluorescent antibody in 25 patients with active Crohn's disease (CDAI > 150 points) before adalimumab therapy was initiated. We applied labeled adalimumab topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF + cells after topical application of labeled adalimumab (Fig. 2a,b) . These specific fluorescence signals were markedly greater than background autofluorescence ( Supplementary Fig. 2a-c) . The mean signal-to-background ratio was 9.74 ± 2.4 (mean ± s.e.m.), whereas the signal-to-noise ratio was 10.96 ± 1.9 (mean ± s.e.m.). Contrast-enhanced imaging showed that positive cells were localized outside of the crypt in the lamina propria (Fig. 2c) . Detailed inspection revealed a membranous fluorescence pattern of mTNF + cells in vivo (Fig. 2d) that was comparable to the pattern seen with confocal imaging of mTNF-expressing cells from biopsies in the same patients (Fig. 2e) . Administration of labeled adalimumab was well tolerated in all patients, and we noted no adverse events.
Although the inflamed mucosal areas in Crohn's disease examined during the molecular imaging procedure had similar macroscopic and histologic signs of inflammation, there were marked interindividual differences regarding the number of mucosal mTNF + cells (Fig. 3a-c) . Quantitative analysis of the in vivo images revealed that some patients had high numbers of mTNF + mucosal immune cells (≥20 cells per confocal image), whereas the other patients had low amounts of mTNF-expressing cells (<20 cells per confocal image) (Fig. 3a) .
Clinical outcome analysis
Following in vivo imaging, we treated the patients with active Crohn's disease with adalimumab and evaluated the clinical response to anti-TNF treatment (Fig. 3d) . The clinical analysis showed that 52% of the patients with Crohn's disease had a clinical response (decrease of the CDAI score ≥ 100 points) after 12 weeks of adalimumab treatment. We then determined the correlation of the mean number of in vivo-detected mTNF + cells per patient to the clinical outcome of adalimumab therapy. The mean number of mTNF + cells per confocal image (± s.e.m.) was 11 ± 2 in patients without subsequent clinical response to adalimumab treatment, whereas we detected a (Fig. 3b) .
To confirm these in vivo molecular imaging results, we stained gut sections from the mucosal area adjacent to the site where molecular imaging was performed ex vivo with labeled adalimumab. Patients with clinical response to adalimumab therapy after 12 weeks had a significantly (P = 0.02) higher mean number of mTNF-expressing cells (24 cells per high-power field) than patients without clinical response (13 cells per high-power field). We identified cells expressing mTNF as lamina propria CD14 + macrophages and some CD4 + T lymphocytes ( Supplementary Fig. 3 ).
We then assessed the sensitivity and specificity for the prediction of clinical response to adalimumab treatment using a discriminative threshold of 20 mTNF + cells per confocal image. Accordingly, we stratified patients into high-mTNF (≥20 cells per confocal image) and low-mTNF (<20 cells per confocal image) groups on the basis of the mean number of mTNF-expressing cells per confocal highpower field in vivo. These groups did not demonstrate any significant difference in inflammatory activity in the colon (Fig. 3c ) or in systemic CRP levels ( Table 1) . However, we found that patients with high numbers of mTNF-expressing cells per confocal image demonstrated a higher probability of clinical response to subsequent adalimumab therapy than patients with low numbers of mTNF + cells (92% versus 15%) (Fig. 3e) . The sensitivity, specificity and accuracy for the prediction of therapeutic responses were 92%, 85% and 88%, respectively. Positive and negative predictive values were 85% and 92% (Table 2) . A comparison of the distribution of the other patient characteristics between responders and nonresponders to Table 1 ).
Further analysis 4 and 12 weeks after adalimumab therapy revealed that patients in the high-mTNF group exhibited a statistically significant reduction in their CDAI score (P = 0.04 and P = 0.02, respectively), whereas patients in the low-mTNF group had no significant reduction in their CDAI score. The mean CDAI score (± s.e.m.) in the former group was 253 ± 29 before adalimumab treatment, but mean values were 117 ± 34 and 93 ± 29 after 4 and 12 weeks after therapy, respectively. In contrast, patients in the latter group showed no significant reduction in CDAI scores after therapy: the mean CDAI score was 295 ± 31 before adalimumab treatment and changed to 238 ± 35 after 4 weeks and to 249 ± 52 after 12 weeks of adalimumab treatment. Following the 12-week therapy, all responders in the high-mTNF group received extended therapy with adalimumab over a period of 12 months. The clinical follow-up demonstrated a sustained highly significant reduction of their CDAI level (P = 0.006), with a mean value of 68 ± 20 at week 52 (Supplementary Fig. 4a) . In contrast to the low-mTNF group where four patients had to undergo surgery, none of the patients in the high-mTNF group had to undergo surgery within 12 months, which underlines the different responses of the two groups to clinical anti-TNF therapy. In addition, we found that patients with high mTNF expression had a significant reduction (P = 0.04) of the mean corticosteroid use in the course of adalimumab therapy (Supplementary Fig. 4b) .
We also evaluated the mean number of in vivo mTNFexpressing cells per patient during the molecular imaging procedure by a receiver operating characteristic (ROC) analysis at the end of the study. The area under curve (AUC) was 0.933 (95% confidence interval 0.917-0.942). The ROC analysis identified a value of ≥20, as an optimum cut-off point to differentiate between patients with high and low numbers of mTNF-expressing cells, with a sensitivity of 84.6% and a specificity of 91.7% for the prediction of response to adalimumab therapy (Supplementary Fig. 2d) .
We next evaluated mucosal healing, defined as absence of mucosal ulcerations during follow-up endoscopy. We performed a follow-up colonoscopy at a mean interval of 17 months (range 10-24 months) in 11 of the 12 patients in the high-mTNF group. In this group, 73% of the patients exhibited mucosal healing during follow-up endoscopy (Supplementary Fig. 5 ). In addition, the histological inflammatory score was significantly reduced during the follow-up examination in the high-mTNF group (P = 0.03) (Fig. 3c) , suggesting that adalimumab induces mucosal healing and histologic suppression of inflammation in the mucosa in these patients.
DISCUSSION
In the present study, we demonstrate that topical application of fluorescent antibodies to TNF in conjunction with CLE can be used for in vivo molecular imaging of mucosal immune cells in Crohn's disease during colonoscopy. We quantitatively assessed the number of immune cells expressing mTNF and correlated this finding with clinical response to subsequent treatment with the antibody to TNF adalimumab. To the best of our knowledge, this is the first report on the use of fluorescent antibodies that conform with good manufacturing practices guidelines for in vivo imaging in humans. Our findings suggest that fluorescent antibodies have a high potential for in vivo imaging in humans with broad applications in clinical medicine.
CLE has emerged as a unique technique for performing real-time in vivo imaging of the mucosa at cellular and subcellular levels 21 and has been used for in vivo molecular imaging procedures 17 . However, in vivo molecular imaging using endomicroscopy in humans has been restricted to labeled peptides with relatively low binding affinity to target structures. In this study, we took advantage of a well-characterized monoclonal antibody against the proinflammatory cytokine TNF that exhibits a high affinity to human mTNF and used this antibody in labeled form for in vivo imaging during colonoscopy in Crohn's disease. Imaging was performed upon topical administration of fluorescent antibody to the most inflamed part of the gut mucosa in active Crohn's disease to identify mTNF-expressing cells, as it was assumed that this area would adequately reflect the highest inflammatory burden for subsequent adalimumab therapy. As the barrier function of intestinal epithelial cells is markedly impaired in active Crohn's disease, topical administration offered the potential advantage of rapid access to the region of interest and appeared to be the ideal approach for delivery of the molecular probe in Crohn's disease. Additionally, as minimal amounts of antibody were sufficient for successful topical visualization of mTNF + cells in intestinal biopsies, it was likely that this approach would minimize the potential risk of allergic reactions to fluorescent adalimumab. The application of this diagnostic procedure was easily implemented into clinical practice, as colonoscopies are routinely performed in patients with Crohn's disease before anti-TNF therapy is initiated to assess the extent and severity of mucosal inflammation 22 .
Topical administration of fluorescent adalimumab permitted molecular in vivo imaging of mTNF + cells with high signal-to-noise and signal-to-background ratios. Similarly, recent reports on molecular imaging using topically delivered fluorescent lectins or labeled heptapeptides showed high signal-to-noise and signal-tobackground ratios, suggesting that local administration of fluorescent agents may result in substantially better values as compared to results obtained after systemic administration of other agents 17, 23, 24 . Thus, topical administration of fluorescent adalimumab enabled rapid visualization of mTNF expression on a cellular level. These findings are probably related to the known high binding affinity of adalimumab to mTNF 19, 20 and the observation that fluorescent antibodies rapidly reach the mucosa where they bind to mTNF + immune cells.
In agreement with previous studies, we identified these mTNF + cells as lamina propria CD14 + macrophages and CD4 + T cells that have a fundamental role in Crohn's disease pathogenesis 2, 19, 25, 26 . Several studies have indicated that clinically effective antibodies to TNF work by inducing T cell apoptosis via binding to mTNF-expressing target cells in Crohn's disease 18, 19, [27] [28] [29] . We found that patients with high numbers of mTNF + immune cells showed considerably higher response rates to adalimumab therapy as compared to patients with low numbers of mTNF + cells. Similarly, histological assessment of mucosal mTNF expression in intestinal biopsies of the patients also showed a substantial correlation with the subsequent response to adalimumab therapy. Although this correlation was weaker than the correlation found in the in vivo molecular imaging study, the presence of similar levels of mucosal inflammation in all patients suggested that the difference in mTNF-expressing cells in vivo between both groups was not the result of varying immune cell infiltration levels, but rather of a difference in the number of mTNF-expressing cells between the patients. These findings suggest that the low clinical response rate in patients with low numbers of mTNF + immune cells is at least partially due to the absence of anti-TNF target cells in the inflamed gut and is thus consistent with the idea of mechanistic failure of adalimumab therapy in mTNF-independent Crohn's disease inflammation. Notably, clinical responses induced by adalimumab therapy in the high-mTNF group were sustained over a follow-up period of 1 year and associated with mucosal healing and histologic suppression of mucosal inflammation on follow-up endoscopy, indicating that mTNF imaging could be used to identify patients with particular beneficial responses to anti-TNF therapy. This concept should now be tested in further randomized studies. These studies should also compare results of mTNF in vivo imaging with adalimumab trough levels as an alternative predictor of responsiveness to adalimumab therapy in Crohn's disease.
Molecular imaging with monoclonal antibodies in humans is currently restricted by regulatory authorities mainly owing to the limitations regarding the approval of using fluorescently labeled antibodies in vivo. Here, we used fluorescent antibodies for molecular imaging in patients with Crohn's disease in vivo to establish a biomarker to differentiate between unlikely and likely responders to a disease-specific therapy. Thus, fluorescent antibodies appear to have considerable potential to serve as biomarkers for decisions on subsequent therapy with biological agents. For instance, endomicroscopic imaging with fluorescent antibodies might be suitable for other autoimmune and chronic inflammatory diseases such as ulcerative colitis, where anti-TNF agents have been successfully used in subgroups of patients 30 . Moreover, in colorectal cancer, where epidermal growth factor receptor (EGFR)-and vascular endothelial growth factor receptor (VEGF)-specific antibodies have been shown to induce clinical responses in subgroups of patients 31, 32 , labeled antibodies against EGFR or VEGF could be used for new diagnostic approaches aimed at predicting subsequent therapeutic responses. This concept is supported by recent studies on molecular imaging in colorectal cancer identifying VEGFexpressing cells using anti-VEGF antibodies and endomicroscopy in xenograft models and tumor samples ex vivo 33 . Finally, given the recent success of neutralizing monoclonal anti-cytokine antibodies in subgroups of patients with autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and psoriasis [34] [35] [36] [37] , in vivo molecular imaging with labeled antibodies could be used for prediction of responders to therapy in these diseases upon topical administration of labeled antibodies (for example, epidermal or intra-articular administration). Thus, molecular imaging with fluorescent antibodies emerges as a potential approach for identifying responders to therapy in patients with chronic inflammatory and autoimmune disorders as well as in cancer. This approach might open new avenues for personalized medicine in Crohn's disease and other disorders.
METhODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METhODS
Labeling of adalimumab with FITC. The investigational product was manufactured in the good manufacturing practice unit of the Department of Pharmacy, Erlangen University Hospital. FITC was covalently conjugated to the human anti-TNF IgG1 monoclonal antibody (adalimumab) (Humira, Abbott Laboratories) by using specific labeling reagents (Thermo Fisher Scientific). Adalimumab was labeled by the manufacturer as required under Chapter 5 of the European GMP guidelines. The concentration of adalimumab was adjusted to 2 mg ml −1 with 50 mM borate buffer (pH 8.5). The protein was added to 37.5 µg FITC (96 nmol). The sample was mixed and protected from light for 1 h at 25 °C. Dye Removal Columns were used to remove free FITC, as described by the manufacturer (Thermo Fisher Scientific). The absorbance of the solution containing the labeled IgG was determined at 280 and 495 nm. The binding molar ratio (F/P ratio) of FITC to adalimumab was calculated as follows: F/P molar ratio = 2.97 A 495 /(A 280 − 0.32 A 495 ). The investigational product contained 1.07 µg µl −1 labeled adalimumab.
SDS-PAGE electrophoresis of fluorescent adalimumab and IgG. Labeled adalimumab and purified human IgG (Innovative Research) were analyzed by the SDS-PAGE Phast System (Amersham Biosciences) or SDS-PAGE Laemmli system. 1 µg of the labeled protein was boiled for 5 min in sample buffer containing mercaptoethanol and applied to an acrylamide gel (PhastGel Gradient 8-25, GE Healthcare Life Sciences or Bio-Rad Mini-PROTEAN Tetra cell). After electrophoresis, the gel was exposed to ultraviolet light for the detection of fluorescence (CabUVIS, Desga-Sarstedt or Bio-Rad Molecular Imager XRS+ System) to exclude unbound FITC in the study medication. Thereafter, the gel was stained by Coomassie.
Ex vivo molecular imaging. A handheld rigid confocal probe (FIVE1, Optiscan) was used for ex vivo studies. The blue laser light incorporated an excitation spectrum of 488 nm and a detection bandwidth of 505-585 nm, obtaining optical sections of 475 × 475 µm. The lateral resolution was 0.7 µm and the optical slice thickness was 7 µm. The depth of this device could be manually adjusted until 250 µm.
Ex vivo molecular imaging was performed using intestinal samples of patients with Crohn's disease (n = 21). Their collection was approved by the Ethics Committee of the Friedrich-Alexander University Erlangen-Nuremberg. Informed consent was obtained from the patients. Tissue samples were rinsed with PBS and incubated with 20 µg labeled adalimumab per 500 µl PBS for 1-10 min. After washing with PBS, specimens were analyzed by confocal laser endomicroscopy.
In addition, some tissues were cut into histological sections for immunohistochemical analysis. These slides were counterstained with an anti-fade medium containing DAPI (Vector Laboratories) and imaged using a SP-5 confocal microscope with a 63×/1.3 NA objective (Leica Microsystems).
Patient population. The in vivo molecular imaging trial was performed as a prospective, monocentric, open-label, single-arm clinical study (investigator-initiated trial). The experiments were not randomized. Approval was granted by Paul-Ehrlich-Institut and the competent Ethics Committee of the University of Erlangen-Nuremberg. The trial was registered at clinicaltrials.gov (study NCT01275508). All patients gave written informed consent to participate in this study.
25 patients (9 female, 16 male) selected consecutively with confirmed Crohn's disease and active disease (CDAI >150 points) were prospectively included in this study. All patients were required to have a clinical indication for an anti-TNF therapy 38 . Concurrent therapies for Crohn's disease, including 5-aminosalicylates, prednisone (≤30 mg d −1 ) and azathioprine, were permitted at stable dosages. Female patients with childbearing potential were required to use a highly effective form of birth control.
Patients were excluded if they had impaired blood clotting, had short bowel syndrome, were pregnant or breast feeding or had received enema therapy within 1 month before inclusion in the study. Patients who had had anti-TNF therapy within the last 12 months were also excluded. Participation in another clinical trial or the administration of other investigational drugs within 4 months prior to the screening visit was not allowed. Other contraindications included moderate to severe heart failure, active tuberculosis or acute infections.
Study design.
Patients were assessed at weeks −1 (visit 1), 0 (visit 2), 1 (visit 3), 5 (visit 4) and 13 (visit 5), with additional telephone interviews at days 1, 14 and 21. The screening of the patients was performed during visit 1. At visit 2, molecular imaging in vivo was performed. At visit 3, subcutaneous adalimumab therapy was initiated (160 mg at visit 3 and 80 mg 2 weeks thereafter). This was followed by 40 mg adalimumab every other week. The CDAI score was assessed during visits 1, 3, 4 and 5. The clinician who determined the CDAI scores during the visits of the patients during the study was blinded to the results of the endoscopic, endomicroscopic and histopathological findings at visit 1. A response was defined as a reduction of the CDAI score ≥100 points 10 at visit 5 as compared to visit 3. The need for surgical intervention after study entry was defined as nonresponse to therapy. Patients with a high mTNF expression were followed for 52 weeks after the induction of the adalimumab therapy. The CDAI score was assessed in these patients during the visit. Adverse events were recorded throughout the study. Normal CRP levels were defined as CRP values <0.5 mg l −1 . Steroid reduction was permitted from week 2 after the initiation of the adalimumab therapy in all patients participating in this study. The tapering regimen was 5-10 mg per week for prednisone 10-30 mg and 2.5 mg per week for prednisone <10 mg.
A follow-up white-light colonoscopy was performed in 11 of 12 patients with high mTNF expression with a mean value of 17 months (range 10-24 months) after initiation of adalimumab therapy. Mucosal ulceration was considered present if one or more of the inspected segments of the ileocolon had ulcerations during the endoscopic procedure. Mucosal healing was defined as the absence of ulcers during the follow-up endoscopy in the group of patients with high mTNF expression 39 .
In vivo molecular imaging. In vivo molecular imaging was performed in patients with Crohn's disease during routine colonoscopy before the initiation of adalimumab therapy. All patients were routinely prepared for colonoscopy using Moviprep (Norgine) for bowel cleansing. Endoscopic examination of the ileum or the colon was performed using a high-resolution white-light video endoscope in which a confocal fluorescence microscope is integrated into the distal tip (Pentax Endomicroscopy System). The endoscope-integrated confocal microscope collected images at a scan rate of 1 frame per second yielding a resolution of 1,024 × 1,024 pixels (1 megapixel) with a dynamically adjustable depth of scanning ranging from 0 to 250 µm. This system used an incident 488-nm wavelength laser and enabled the detection of fluorescence between 205-and 585-nm wavelengths. The lateral and axial resolution was 0.7 µm, enabling a confocal image view of 475 × 475 µm. The laser power could be manually adjusted between 0 and 1,000 µW.
Conventional white-light endoscopy was performed to select the mucosal sites with the heaviest inflammation for the subsequent endomicroscopic procedure. Sites with ulcers and active bleeding were excluded because of the risk of imaging artifacts. The mucosal site of interest was first intensively washed with water in order to remove mucus and debris from the surface layer. Next, the mucosa was endomicroscopically inspected to exclude unspecific background signals due to autofluorescence of the tissue. 20 µg of labeled antibody was then topically administered in a 1-ml watery dilution to the surface of the mucosa via a standard spray catheter (Olympus). After an incubation time of 1 min, excess antibody was removed by gently rinsing the mucosa with water. Afterwards, imaging was performed using the endomicroscopic confocal fluorescence imaging system which uses a laser light with a wavelength of 488 nm. The labeled moiety of the adalimumab antibody, which was bound to mTNF + lamina propria cells, was excited at 488 nm and emitted a signal with a wavelength of 518 nm. These light waves therefore enabled detection of fluorescent adalimumab binding on a cellular level, indicating mTNF + cells in the lamina propria. Digital images of the area were stored as high-quality frames for documentation and later analysis. We collected fluorescence images in vivo at 1 frame per second up to depths of 50 µm beneath the mucosal surface at a resolution of 1 megapixel. This staining procedure was done in the same mucosal area four times altogether. Each patient topically received a total of 80 µg adalimumab, 183 ng fluorescein and 32 ng isothiocyanate. 
